Jia, Haiyan
Mai, Jiajia
Wu, Min
Chen, Hong
Li, Xiaojiao
Li, Cuiyun
Liu, Jingrui
Liu, Chengjiao
Hu, Yue
Zhu, Xiaoxue
Jiang, Xiuhong
Hua, Bo
Xia, Tian
Liu, Gang
Deng, Aiyun
Liang, Bo
Guo, Ruoling
Lu, Hui
Wang, Zhe
Chen, Huanming
Zhang, Zhijun
Zhang, Hong
Niu, Junqi
Ding, Yanhua
Funding for this research was provided by:
Capital Construction Funds within the provincial budget (2020C038-1)
Shanghai Zhimeng Biopharma, Inc
Article History
Received: 28 October 2022
Accepted: 6 March 2023
First Online: 16 March 2023
Declarations
:
: The study protocol was approved by the Institutional Review Board of the First Hospital of Jilin University, and conducted according to the Declaration of Helsinki, Guidelines for Good Clinical Practice, and local laws and regulations. The ethics approval number is 20Y201-006. All patients provided written informed consent.
: Not applicable.
: XJ, BH, TX, GL, AD, BL, RG, HL, ZW, HC, and ZZ are employees of Shanghai Zhimeng Biopharma, which sponsored this study. The other authors declare no conflicts of interest.